newscontact us

ThermoGenesis Announces New Cord Blood Products Distribution Agreements

AGREEMENTS EXPAND PRESENCE IN EUROPE, THE MIDDLE EAST AND LATIN AMERICA

RANCHO CORDOVA, CA, September, 19, 2012—ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of enabling technologies for the processing, storage and administration of cell therapies, today said it has signed two additional new channel partner agreements as part of its continuing program to enhance its distribution, technical service and clinical support initiatives of its cord blood products.

Under a new agreement with HVD Biotech Vertriebs GmbH (“HVD”), HVD will have exclusive distribution rights for the AXP® AutoXpress® System and BioArchive® System in 10 European countries—including Germany, Austria, and the Czech Republic—and 13 Middle Eastern countries, including Egypt, Saudi Arabia and the United Arab Emirates.

The Company also announced an expanded distribution agreement with Comércio Exportação e Importação de Materiais Médicos Ltda (“CEI”), under which CEI will have exclusive distribution rights for the AXP and BioArchive in nine Latin American countries, including Mexico, Brazil, and Argentina. CEI has been distributing the BioArchive System and ThermoGenesis manual cord blood processing and storage sets for cryopreservation of 25mL concentrated samples in Latin American countries since 2000.

“These new integrated agreements, combined with our recently announced distribution agreement in other European markets with Concessus are important milestones in our strategy to provide a customer-centric focus that incorporates sales, service and support for our cord blood product portfolio. We believe these new partners will further both our existing customer relationships and market expansion efforts for our best-in-class offerings,” said Hal Baker, Vice President of Commercial Operations for ThermoGenesis.

“We look forward to working with ThermoGenesis on further developing these important European and Middle Eastern markets. We believe there are significant opportunities with cord blood banks in these regions and that ThermoGenesis’ offerings provide important competitive advantages,” said Hermanus van Duyne, Managing Director of HVD.

“We have had a very positive experience with ThermoGenesis over the past 12 years and are excited about the new market opportunities under our expanded relationship with the Company,” said Paulo Pacheco, Chief Executive Officer of CEI.

“These three new distribution agreements spanning three continents should provide us important leverage in these international markets as we seek to facilitate adoption of automation in the cord blood market and expand our footprint outside of the U.S.,” said Matthew Plavan, Chief Executive Officer of ThermoGenesis.

About HVD Biotech Vertriebs GmbH
HVD Biotech Vertriebs GmbH (www.hvdlifesciences.com) was established in 1995 with the purpose to distribute products and services in the broader fields of Life Sciences and Biotechnology products. HVD associates with innovative companies for research and advanced diagnostic products and services, and support customers with exceptional service and technical support when introducing new frontier lab techniques and methods. With headquarters in Vienna and field offices in East Europe, Athens, Moscow, Hong Kong, Riyadh, Sharjah, Cairo and Mexico City as well as an extensive network of over 40 partner companies ideally positioned to provide customers with fast and top quality service.

About CEI
CEI is a leader in its field and has more than 40 years experience in sales, marketing and manufacturing of medical devices, providing quality products and services. CEI sells equipment to a large variety of customers, blood banks, research institutes, universities and hospitals throughout Latin America.

About ThermoGenesis Corp.
ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These include:

  • The BioArchive® System, an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant.
  • AXP® AutoXpress® Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP® MarrowXpress® and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. The MXP is used for the preparation of cell concentrates, including stem cells from bone marrow aspirates in the laboratory setting.
  • The Res-Q® 60 BMC/PRP (Res-Q), a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates and whole blood for platelet rich plasma (PRP).

This press release contains forward-looking statements. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors including timing of FDA and foreign regulatory approvals, changes in customer forecasts, our failure to meet customers’ purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers’ products, introduction timing and acceptance of our new products scheduled for fiscal years 2012 and 2013, and introduction of competitive products and other factors beyond our control could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2012 and 2013. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption “Risk Factors” in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

ThermoGenesis Corp.
Web site: http://cescatherapeutics.com
Contact: Investor Relations
+1-916-858-5107, or
ir@thermogenesis.com